1. Calmara wants users to snap a photo of their partner’s genitals to determine STI status, but this method is unreliable and not recommended.
2. Other startups are taking a more responsible approach to accessible STI testing by using validated lab tests for detection.
3. Calmara’s lack of medical involvement, unclear data privacy measures, and potential legal risks make it a dangerous and unreliable tool for assessing sexual health.
Calmara is a company that wants users to take photos of their partner’s genitals and use AI to determine if they are clear of STIs. This approach is highly irresponsible and inaccurate, as most STIs are asymptomatic and require blood or urine samples for diagnosis. Other startups, such as TBD Health, are approaching accessible STI testing in a more responsible way, using rigorous tests with known validation rates.
Calmara’s marketing suggests it is a tool for unprotected sex, but the CEO clarifies that it is a lifestyle product, not a medical app. HeHealth, the company behind Calmara, claims their AI is 65-90% accurate and offers a platform for users to connect with partner clinics for comprehensive screenings. However, there are privacy concerns regarding how user data and intimate photos are handled by these companies.
Despite claims of compliance with HIPAA regulations, Calmara’s privacy policy raises questions about how user information is shared with service providers and partners. There is also a concern about minors using the platform, as Calmara could end up in possession of child sexual abuse material. Overall, Calmara represents the dangers of over-hyped technology in the sexual health space, giving users a false sense of security and potentially risking their privacy and legal consequences.